Seaport Therapeutics
Seaport Therapeutics is a clinical-stage company developing novel neuropsychiatric medicines using its proprietary Glyph platform. The Director of Statistical Programming will build and lead the in-house Statistical Programming function within the Biometrics department, providing strategic oversight of vendor programming, performing hands-on SAS/R programming, and ensuring submission-ready, CDISC-compliant deliverables.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
Associate Director, Statistical Programming
Corcept Therapeutics
Manager of Statistical Programming
Rezolute
Senior Manager, Statistical Programming
immunomeinc
Associate Director, Statistical Programming
Travere Therapeutics
Statistical Programmer
Bristol Myers Squibb
Manager 1, Statistical Programming
lifelancer